The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
PCSK9‐deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
Open accessAbstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a liver‐secreted plasma enzyme, restricts hepatic uptake of low‐density lipoprotein (LDL) cholesterol by promoting the degradation of LDL receptors (LDLR). PCSK9 and LDLR are also expressed in insulin‐producing pancreatic islet β cells, possibly affecting the function of these cells. Here we show that, compared to control mice, PCSK9‐null male mice over 4 months of age carried more LDLR and less insulin in their pancreas; they were hypoinsulinemic, hyperglycemic and glucose‐intolerant; their islets exhibited signs of malformation, apoptosis and inflammation. Collectively, these observations suggest that PCSK9 may be necessary for the normal function of pancreatic islets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Self-citationSecreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681 · cited 1×
“the liver of transgenic mice has the opposite effect [3,8–12].”
BackgroundSex and depot differences in adipocyte insulin sensitivity and glucose metabolism
Macotela, Y., Boucher, J., Tran, T. T., & Kahn, C. R. (2009) · Diabetes · doi:10.2337/db08-1054 · Cited by 401
The activation and physiological functions of the proprotein convertases
Seidah, N. G., Mayer, G., Zaid, A., Rousselet, E., Nassoury, N., Poirier, S., Essalmani, R., & Prat, A. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.01.030 · Cited by 314 · cited 1×
“Collectively, they are responsible for the activation of a wide variety of precursor proteins by endoproteolysis after selected residues [1].”
BackgroundSelf-citationEffect of mutations in the PCSK9 gene on the cell surface LDL receptors
Cameron, J., Holla, Ø. L., Ranheim, T., Kulseth, M. A., Berge, K. E., & Leren, T. P. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl077 · Cited by 258 · cited 1×
“According to the current prevailing model, the convertase attaches to the receptor and directs it to endosomes/lysosome-like compartments for degradation [4–6].”
BackgroundThe cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR
Nassoury, N., Blasiole, D. A., Tebon Oler, A., Benjannet, S., Hamelin, J., Poupon, V., McPherson, P. S., Attie, A. D., Prat, A., & Seidah, N. G. (2007) · Traffic · doi:10.1111/j.1600-0854.2007.00562.x · Cited by 248 · cited 1×
“According to the current prevailing model, the convertase attaches to the receptor and directs it to endosomes/lysosome-like compartments for degradation [4–6].”
BackgroundSelf-citationHuang, L., Shen, H., Atkinson, M. A., & Kennedy, R. T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.21.9608 · Cited by 107
Lalanne, F., Lambert, G., Amar, M. J. A., Chétiveaux, M., Zaïr, Y., Jarnoux, A.-L., Ouguerram, K., Friburg, J., Seidah, N. G., Brewer, H. B., et al. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400396-jlr200 · Cited by 104
Self-citation
Cited by
The biology and therapeutic targeting of the proprotein convertases
Seidah, N. G., & Prat, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3699 · Cited by 759
Self-citationSeidah (2014) · doi:10.1161/circresaha.114.301621 · Cited by 596
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
Schmidt, A. F., Swerdlow, D. I., Holmes, M. V., Patel, R. S., Fairhurst-Hunter, Z., Lyall, D. M., Hartwig, F. P., Horta, B. L., Hyppönen, E., Power, C., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30396-5 · Cited by 380
PCSK9 inhibitors: A new era of lipid lowering therapy
Chaudhary, R., Garg, J., Shah, N., & Sumner, A. (2017) · World Journal of Cardiology · doi:10.4330/wjc.v9.i2.76 · Cited by 299
Urban, D., Pöss, J., Böhm, M., & Laufs, U. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.056 · Cited by 286
Wang, L., Li, S., Luo, H., Lu, Q., & Yu, S. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02477-0 · Cited by 271
Diagnosis and treatment of familial hypercholesterolaemia
Hovingh, G. K., Davidson, M. H., Kastelein, J. J. P., & O'Connor, A. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht015 · Cited by 256
Da Dalt, L., Ruscica, M., Bonacina, F., Balzarotti, G., Dhyani, A., Di Cairano, E., Baragetti, A., Arnaboldi, L., De Metrio, S., Pellegatta, F., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy357 · Cited by 209
TANG, Z., JIANG, L., PENG, J., REN, Z., WEI, D., WU, C., PAN, L., JIANG, Z., & LIU, L. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.1072 · Cited by 208
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Colhoun, H. M., Ginsberg, H. N., Robinson, J. G., Leiter, L. A., Müller-Wieland, D., Henry, R. R., Cariou, B., Baccara-Dinet, M. T., Pordy, R., Merlet, L., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw292 · Cited by 172
Bergeron, N., Phan, B. A. P., Ding, Y., Fong, A., & Krauss, R. M. (2015) · Circulation · doi:10.1161/circulationaha.115.016080 · Cited by 171
Inhibiting PCSK9 — biology beyond LDL control
Stoekenbroek, R. M., Lambert, G., Cariou, B., & Hovingh, G. K. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0110-5 · Cited by 141
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
Schulz, R., Schlüter, K.-D., & Laufs, U. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0463-z · Cited by 137
Targeting PCSK9 for hypercholesterolemia
Norata, G. D., Tibolla, G., & Catapano, A. L. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140025 · Cited by 127
Statins and risk of type 2 diabetes: mechanism and clinical implications
Laakso, M., & Fernandes Silva, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1239335 · Cited by 82
PCSK9: Regulation and Target for Drug Development for Dyslipidemia
Burke, A. C., Dron, J. S., Hegele, R. A., & Huff, M. W. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104944 · Cited by 74
Cao, Y., Liu, H., Dong, Q., Li, S., & Li, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13235 · Cited by 61
Arsenault, B. J., Pelletier-Beaumont, E., Alméras, N., Tremblay, A., Poirier, P., Bergeron, J., & Després, J.-P. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.07.010 · Cited by 58
Nelson, C. P., Lai, F. Y., Nath, M., Ye, S., Webb, T. R., Schunkert, H., & Samani, N. J. (2019) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.118.002196 · Cited by 55
Roubtsova, A., Chamberland, A., Marcinkiewicz, J., Essalmani, R., Fazel, A., Bergeron, J. J., Seidah, N. G., & Prat, A. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m061952 · Cited by 55
Self-citationInsight into the Evolving Role of PCSK9
Maligłówka, M., Kosowski, M., Hachuła, M., Cyrnek, M., Bułdak, Ł., Basiak, M., Bołdys, A., Machnik, G., Bułdak, R. J., & Okopień, B. (2022) · Metabolites · doi:10.3390/metabo12030256 · Cited by 41
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
Bell, A. S., Wagner, J., Rosoff, D. B., & Lohoff, F. W. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105155 · Cited by 36
van Loon, N. M., Ottenhoff, R., Kooijman, S., Moeton, M., Scheij, S., Roscam Abbing, R. L. P., Gijbels, M. J. J., Levels, J. H. M., Sorrentino, V., Berbée, J. F. P., et al. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.311168 · Cited by 25
PCSK9 inhibition and cholesterol homeostasis in insulin producing β-cells
Päth, G., Perakakis, N., Mantzoros, C. S., & Seufert, J. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01751-6 · Cited by 24
“These mice showed accumulation of cholesterol in islets and impaired glucose-stimulated insulin secretion irrespective of gender and diet [68, 69].”
Background
Metadata
- Authors
- Mbikay, M., Sirois, F., Mayne, J., Wang, G.-S., Chen, A., Dewpura, T., Prat, A., Seidah, N. G., Chretien, M., & Scott, F. W.
- Venue
- FEBS Letters
- Publisher
- Wiley
- Published
- 2009-12-16
- Volume
- 584
- Issue
- 4
- Pages
- 701-706
- ISSN
- 0014-5793 (ISSN-L)
- 1873-3468
- OpenAlex
- W2103518970
- Cited by
- 197
- References
- 8
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.